http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bc67de5aff23d7926130022498fd3ed6
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Laubach |
| name | Jacob Laubach |
| given-name | Jacob |
| organization-name | Dana Farber Cancer Institute, Boston, Massachusetts 02115; Harvard Medical School, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, MA, USA. jacobp_laubach@dfci.harvard.edu. 1Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, MA;; Department of Medicine, Harvard Medical School, Boston, MA; Paul G. Richardson, Robert Schlossman, Irene M. Ghobrial, Nikhil Munshi, Jacob Laubach, Teru Hideshima, Kathleen Colson, and Kenneth C. Anderson, Dana-Farber Cancer Institute; Noopur Raje, Massachusetts General Cancer Center, Boston, MA; Jeff Wolf and Tom Martin, University of California San Francisco, San Francisco; David Irwin, Alta Bates Cancer Center, Berkeley; Amrita Krishnan, City of Hope, Duarte, CA; Andrzej Jakubowiak, University of Michigan, Ann Arbor; Jeff Zonder, Karmanos Cancer Center,... Medical Oncology Dana‐Farber Cancer Institute and Harvard Medical School Boston Massachusetts Department of Hematology and Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA Dana Farber Cancer Institute, Boston, MA; Jerome Lipper Multiple Myeloma Center and; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;; Department of Medicine, Harvard Medical School, Boston, MA; and The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA Dana-Farber Cancer Institute, Boston, MA; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA Dana‐Farber Cancer Institute Boston MA USA Dana Farber Cancer Institute Harvard Medical School Jerome Lipper Multiple Myeloma Center Boston MA USA Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA, USA Center for Prevention of Progression of Blood Cancers Dana‐Farber Cancer Institute Boston Massachusetts; Department of Medical Oncology, Dana‐Farber Cancer Institute Harvard Medical School Boston Massachusetts Department of Medical Oncology Dana‐Farber Cancer Institute Harvard Medical School Boston MA 02215 USA Authors' Affiliations: 1Beth Israel Deaconess Medical Center; 2Dana Farber Cancer Institute; 3Massachussetts General Hospital, Boston, Massachusetts; and 4Rambam Medical Center, Haifa, Israel Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina, USA Dana Farber Cancer Institute Boston Massachusetts USA Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Dana-Farber Cancer Institute, Boston, MA Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA Department of Hematology/Oncology, Dana-Farber Cancer Institute, Boston, MA; Dana‐Farber Cancer Institute Harvard Medical School Boston MA USA From the Dana–Farber Cancer Institute, Boston. |
Incoming Links
Total number of triples: 99.